A Silicon Valley startup, Preventive, is making strides towards the potential creation of genetically engineered babies, with influential tech leaders backing its mission to eliminate hereditary diseases through gene editing. Founded by Lucas Harrington earlier in 2024, the public benefit corporation has already secured $30 million in funding. Notable investors include Sam Altman of OpenAI and Brian Armstrong, CEO of Coinbase.
Headquartered in San Francisco, Preventive’s primary goal is to demonstrate the safety and transparency of gene-editing technologies before any applications in human embryos are made. Harrington expressed his belief on social media platform X, stating, “If proven safe, this could be one of the most important health technologies of our lifetimes.” He emphasized the need for rigorous research and regulatory oversight, acknowledging the delicate nature of embryo editing.
Harrington highlighted the potential benefits of embryo editing, which include precision and efficiency. Yet he cautioned against the risks posed by unregulated experimentation, noting that limited expert involvement could lead to dangerous shortcuts that endanger patients. “Our goal is straightforward: to determine through rigorous preclinical work whether preventive gene editing can be developed safely to spare families from severe disease,” he added. “If our research shows it cannot be done safely, that conclusion is equally valuable.”
The startup’s ambitions echo past controversies in the field. In 2018, He Jiankui, a Chinese scientist, claimed to have created the first gene-edited babies, a move that resulted in his imprisonment for illegal medical practices. His work sparked significant ethical debates, leading to calls from American researchers for a global suspension of germline editing practices.
In 2019, U.S. senators proposed a unified approach to establish international standards for germline gene editing, aimed at preventing unethical researchers from exploiting countries with lax regulations. The sensitivity of the subject is underscored by U.S. federal law, which prohibits the use of federal funds for human germline gene therapy research, mainly due to ethical concerns regarding the potential long-term impacts on future generations.
Although the U.S. government restricts federal funding for such research, there are no prohibitions against private funding. Therefore, it is feasible for privately funded labs to conduct non-clinical human gene therapy research. However, any attempt to commercialize such therapies would require approval from the Food and Drug Administration (FDA) for clinical studies and marketing.
As Preventive forges ahead, the implications of its research could reshape the future of genetic disease treatment. The outcome of its endeavors may not only influence medical practices but also stir further discussions about the ethical dimensions of human genetic modification.
